A preclinical finding illustrated that triple receptor agonists of GLP-1, GIP, and the glucagon receptor attenuate AD neuropathology in transgenic mice with mutant APP by reducing the formation of Aβ (Tai et al. 2018). This evidence concerns the gene GCGR and Alzheimer disease.